Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bayer Stops Regorafenib Trial Early on Positive Phase III Data

Oct. 26 (Bloomberg) -- Bayer AG announced positive results from its phase III trial evaluating regorafenib compound for the treatment of patients with metastatic colorectal cancer whose disease has progressed after approved standard therapies. The trial met its primary endpoint of statistically significantly improving overall survival and patients in the placebo arm will be offered treatment with regorafenib, the company said in an e-mailed statement today.

Link to Company News:{BAYN GR <Equity> CN <GO>}

To contact the editor responsible for this story: Mariajose Vera at mvera1@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.